The Mechanism of Combination using mTORC1/2 Inhibitor and Imatinib to Suppress Cell Proliferation of Ph +ALL Cell Line
Abstract
To investigate the anti-leukemia effect and mechanism of mTORC1/2 inhibitor PP242 combined with imatinib (IM) on the proliferation of Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15. Methods SUP-B15 cell line was treated with PP242, imatinib (IM), or PP242 plus IM for 72 h, IC50 values (the concentration of drug required to kill 50% of the cells) and the combination index (CI ) of synergistic cytotoxicity was determined using MTT methods. The expressions of PI3K/Akt/mTOR and apoptosis associated proteins were examined by Western blot test. Results The IC50 value of IM alone was (1.50±0.09) μmol/L, however, the IC50 values were (0.81±0.030) μmol/L, (0.36±0.140) μmol/L and (0.02±0.002) μmol/L combined with 20 nmol/L, 30 nmol/L and 50 nmol/L of PP242, and the CI values were 0.764, 0.545 and 0.507, indicating two drugs had highly synergistic effect on anti-proliferation in the SUP-B15 cell line. The expressions of p-Akt, p-4EBP1, p-elF4E, p-cAbl, p-mTOR and p-P70 were down-regulated significantly in a dose-dependent and time-dependent manner after PP242 treatment．Compared with PP242 or IM alone, the down-regulation of PI3K/Akt/mTOR signaling pathway and the up-regulation of the apoptosis associated proteins (bax and cleaved caspase-3) were more significant in the combination of two drugs. Conclusion The combination of IM and PP242 could increase the inhibition of PI3K/Akt/mTOR signaling pathway and apoptosis mediated by bax and caspase-3 in SUP-B15 cell line.
Keywords: Ph+ acute lymphoblastic leukemia mTORC1/2, Akt PP242, Imatinib
Full Text:
PDFReferences
TASIAN SK. TEACHEY DT, RHEINGOLD SR. Targeting the Pl3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol,2014(4) ; 108. doi: 10. 3389/fonc. 2014.00108.
KHARAS MG, DEANE JA, WONG S, et al. Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood, 2004,103(11):4268-4275.
GUERTIN DA, SABATINI DM. The pharmacology of mTOR inhibition. Sci Signal, 2009, 2 ( 67 ): pe24. doi; 10.1126/scisignal. 267pe24.
MOHI MG, BOULTON C, GU TL, et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A,2004 ,101(9) :3130-3135.
BECKER MN, WU KJ, MARLOW LA, et al. The combination of an mT()Rcl/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol. 2014, 32 (3):317-326.
CYBULSKIN, HALL MN. TOR complex 2: a signaling pathway of its own. Trends Biochem Sci, 2009, 34 ( 12 ) : 620- 627.
TABERNEROJ, ROJO F. CALVO E, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol,2008,26(10): 1603-1610.
ASNAGHI L. CALASTRETTI А, BEVILACQUA A, et al. Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt. Oncogene»2004123 (34): 5781-5791. 229
HUGLE M. FULDA S. Dual phosphatidylinositol 3-kinase/ mammalian target of rapamycin inhibitor nvp-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma. Cancer Let .2015 ,360( 1): 1-9.
RODRIK-OUTMEZGUINE VS, CHANDARLAPATY S, PAGANO NC. et al. mTOR kinase inhibition causes feedback-dependent biphasic regulation of АКТ signaling. Cancer Discov.2011.1(3): 248-259.
SONENBERG N. HINNEBUSCH AG. Regulation of translation initiation in eukaryotes:mechanisms and biological targets. Cell.2009.136(4) :731-745.
CHANG F, LEEJT. NAVOLANIC PM. Et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation; a target for cancer chemotherapy. Leukemia,2003 ,17(3);590-603.
LIU P, CHENG H, ROBERTS TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov,2009,8(8) :627-644.
TASIAN SK. TEACHEY DT, RHEINGOLD SR. Targeting the Pl3K/mTOR pathway in pediatric hematologic malignancies. Front Oncol, 2014 ( 4 ): 108 [2016-03-08]. https; //www. ncbi. nlm. nih. gov/pmc/articles/pmid/ 24904824/. doi: 10. 3389/fonc. 2014. 00108.
CHEN YL, LAW PY, LOH HH. Inhibition of PI3K/Akt signaling;an emerging paradigm for targeted cancer therapy. Curr Med Chem Anti-cancer Agents,2005,5(6);575-589. SCHOLLS, BONDEVA T, LIU Y. elal. Additive effects of Pl3-kinase and МАРК activities on NBl cell granulocyte differentiation; potential role of phosphatidylinositol 3-kinase gamma. J Cancer Res Clin Oncol,2006,134(8):861-872.
PROVENCIO JJ. Inflammation in subarachnoid hemorrhage and delayed deterioration associated with vasospasm: a review. Acta Neurochir Suppl.2013 ,115 ;233-238.
WANG HC, YANG TM. LIN WC, et al. The value of serial plasma and cerebrospinal fluid nuclear and mitochondrial deoxyribonucleic acid levels in aneurysmal subarachnoid hemorrhage. J Neurosurg,2013 ,118( 1): 13-19.
ZHANG Q. RAOOF M, CHEN Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature,2010.464(7285): 104-107.
MALIK AN, SHAHNI R. RODRIGUEZ-DE-LEDESMA A, et al. Mitochondrial DNA as a non-invasive biomarker: accurate quantification using real time quantitative PCR without co-amplification of pseudogenes and dilution bias. Biochem Biophs Res Commun,2011,412(1): 1-7.
YATSUSHIGE H, CALVERT JW, CAHILL J, et al. Limited role of inducible nitric oxide synthase in blood-brain barrier function after experimental subarachnoid hemorrhage. J Neurotrauma,2006,23( 12): 1874-1882.
GARG АГ), NOWIS D, GOLAB J, et al. Immunogenic cell death, DAMPs and anticancer therapeutics; an emerging amalgamation. Biochim Biophys Acta,2010,1805(1): 53-71.
LAM NY, RAINER TH, WONG LK, et al. Plasma DNA as a prognostic marker for stroke patients with negative neuroimaging within the first 24 h of symptom onset. Resuscitation,2006,68( 1):71-78.
ZHANG Q, ITAGAKI K. HAUSER CJ. Mitochondrial DNA is released by shock and activates neutrophils via p38 map kinase. Shock.2010.34(1):55-59.
WEST AP, SHADEL GS, GHOSH S. Mitochondria in innate immune responses. Nat Rev Immunol,2011,11(6): 389-402.
WALKO TD 3rd. BOLA RA. HONG JD. et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury. Shock, 2014 , 41 ( 6 ): 499- 503.
DHAR R. DIRINGER MN. The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage. Neurocrit Care, 2008. 8 ( 3 ): 404- 412.
WEST AP. KOBLANSKY AA, GHOSH S. Recognition and signaling by toll-like receptors. Annu Rev Cell Dev Biol, 2006,22 ;409-437[2016-04-10 . http://www. annualreviews. org/doi/10. 1146/annurev. cell bio. 21. 122303. 115827.
LEESH, LEE JG, KIM JR. et al. Toll-like receptor 9- mediated cytosolic phospholipase A2 activation regulates expression of inducible nitric oxide synthase. Biochem Biophys Res Commun,2007,364(4):996-1001.
MA CX. YIN WN, CAI BW, et al. Toll-like receptor4/ nuclear factor-kappa b signaling detected in brain after early subarachnoid hemorrhage. Chin Med J (Engl), 2009, 122 (13): 1575-1581.
Refbacks
- There are currently no refbacks.
